Phaseline

Targets › PSENEN

PSENEN (Gamma-secretase subunit PEN-2): drug programs, companies and trials

3 programs from 3 companies in 11 trials: 5 Phase 1, 5 Phase 2, 1 Phase 4; Oncology; next expected readout Mar 2027.

Essential subunit of the gamma-secretase complex, an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (amyloid-beta precursor protein). The gamma-secretase complex plays a role in Notch and Wnt signaling cascades and regulation of downstream processes via its role in processing key regulatory proteins, and by regulating cytosolic CTNNB1…. (UniProt, Q9NZ42)

Open in Phaseline: the race on PSENEN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNirogacestat
Gamma-secretase inhibitor
APH1A, PSENEN, APH1B, PSEN1, NCSTNPhase 4Desmoid TumorMay 2027
Children's Oncology GroupNirogacestat Hydrobromide
Gamma-secretase inhibitor
APH1A, PSENEN, APH1B, PSEN1, NCSTNPhase 2Desmoid FibromatosisDec 2032
GSKNirogacestat
Gamma-secretase inhibitor
APH1A, PSENEN, APH1B, PSEN1, NCSTNPhase 1Multiple Myeloma; Tumor; Desmoid Tumor; AIDS-Related Kaposi SarcomaMar 2027

Conditions

Multiple Myeloma (5) Desmoid Tumor (3) Tumor (1) AIDS-Related Kaposi Sarcoma (1) Desmoid Fibromatosis (1)

Modalities

small molecule (2), mixed (1)

Companies

GSK (1) SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (1) Children's Oncology Group (1)

Related targets

APH1A (3) APH1B (3) PSEN1 (3) NCSTN (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.